Genialis(TM) krasID: a First-in-Class Biomarker to Predict Response & Benefit of KRAS Inhibitors

Time: 3:15 pm
day: Day One Track A PM


• Genialis krasID is the first biomarker of its kind, using RNAseq and machine learning to capture a complete picture of a tumor’s vulnerability to KRAS inhibition

• The biomarker accurately predicts response and stratifies benefit in real world patient data, showing high concordance with published clinical trial results

• The biomarker is designed to perform across the spectrum of KRASi mechanisms, mutations and histologies